Mission
Salix is committed to being the leading U.S. specialty pharmaceutical company licensing, developing and marketing innovative products to health care professionals to prevent or treat
gastrointestinal disorders in patients while providing rewarding opportunities for our employees and creating exceptional value for our stockholders.
Company Strategy
In-license selective late-stage/marketed products
Our “search and development” efforts are designed to identify and acquire late-stage and/or marketed proprietary pharmaceutical products for the treatment of gastrointestinal disease that have an
existing base of safety and efficacy data. This focus on late-stage products serves to reduce the risk, time and expense Salix invests in products compared to the investment typically associated with the research
and early development phases of pharmaceutical products.
Outsource low-margin, capital-intensive operations
We focus our investment of time and energy on maximizing the commercial potential of our products. Operations such as manufacturing are outsourced. Resources are not tied up in “bricks and mortar”
but rather invested in activities directed toward increasing product sales.
Sell products through a specialty sales force
Salix has a direct sales force to promote its products to the fastest-adopting, highest-prescribing physicians in the U.S. responsible for treating gastrointestinal disease. We believe that our
specialty sales force - and the high level of service we are able to provide - allows us to capitalize on the opportunity to build a franchise with the gastroenterology community. We also believe
that our specialty sales force allows us to attain the higher profit margins and benefits of direct control over distribution that comes with selling products directly.
Growth by leveraging our product development and product sales infrastructure
We will grow our business by adding new products to our portfolio. We intend to add new product opportunities by:
- expanding the indications for our current products.
- in-licensing or acquiring new products.
- co-promoting selected third-party products.
Focus on the U.S. marketplace
The U.S. represents the largest pharmaceutical market in the world. Salix markets its products to gastroenterologists in the U.S. through its own specialty sales force. We will form strategic alliances to
market our products outside the U.S. in order to avoid the significant costs, risks and infrastructure inherent in assembling an international sales force.
Click here for Latest News and Press Releases